14th Annual Northeast Regional Hematology Oncology Pharmacists Symposium

EVENT DETAILS

14th Annual Northeast Regional Hematology Oncology Pharmacists Symposium - Virtual for 2020!

Thursday, October 8, 2020
PharmCon Online Classroom
Web address to be provided

Dates

8:00 AM - 5:30 PM

Total Credits

18 Contact Hour(s)

Target Audience

Nurse, Pharmacist

Cost

$129.00

Registration closes on 10/10/2020 at 5:30 PM

Early Registration: $99.00

Cost After 9/18/2020: $129.00

On-Site Registration: $129.00

Join us for the 14th Annual NEHOPS Conference – right from your own computer! This annual gathering of hematology and oncology pharmacists provides an incredible opportunity to learn from top experts, earn live CE credits, and network with peers. Though this year’s event is fully online, you’ll still be able to do all of these things! In fact, we’ve extended our 2020 conference to three days, increasing the number of live CE you can earn to 18 contact hours. Need to miss a session or even a full day? No problem. Conference attendees will have access to on-demand webcasts of all sessions (with home study CE credits available). On-demand webcasts will be available shortly after live sessions run and remain available to conference attendees for one full week (through 10/17/20).

Review this year’s agenda below and register today! You’ll pay just $99 if you register by 9/18/2020.

THURSDAY KEYNOTE ADDRESS (with CE credit)

Stronger Together

Colleen Kelly Alexander, Survivor. Thriver. Motivational Speaker.
Colleen Kelly Alexander is a lifelong athlete and motivational speaker who inspires positive change, contribution, determination and actionable gratitude. With her indomitable spirit and incredible story of survival, Colleen teaches others how to aim higher, be stronger and use adversity as a catalyst to make the world a better, brighter place.

SATURDAY KEYNOTE ADDRESS (with CE credit)

How Did We Get Here? Pharmacy Burnout, Etiology, Consequences, and Solutions

Alex Barker, PharmD, Founder and head coach at TheHappyPharmD.com
Everyone talks about it, but little seems to be accomplished. Burnout appears rampant in all areas of healthcare, but particularly pharmacy regardless of setting.
What are the unique causes of burnout in pharmacists? What trends are we observing in the literature? Is there hope for pharmacy to become unburned? In this presentation, you will learn the answers to these questions. By the end, you'll have a better understanding of how your institution influences your job satisfaction and ideas on how your work environment could improve.

AGENDA

Scheduled CE Activities Thursday, October 8, 2020

NEHOPS Day 1 - Opening Remarks

8:30 AM - 8:45 AM

Join Pharmacist Kevin Hope for an introduction and welcome to the first day of NEHOPS.

Pharmacist Learning Objectives

Nurse Learning Objectives

Faculty

Kevin Hope, RPh
Clinical Education Specialist and Continuing Education Administrator, PharmCon, Inc.; Advisory Board Member, Paradigm Education Solutions; Nuclear Pharmacist, Triad Isotopes

ACPE UAN

NO CREDIT (Knowledge-Based)

Credits
0

Handouts

Supported By
PharmCon

Stronger Together

8:50 AM - 9:50 AM

This session seeks to inspire positive change, contribution, determination and actionable gratitude among the pharmacy staff. Actionable mechanisms are discussed that enable participants to aim higher, be stronger and use adversity as a catalyst for improving patient care. Having overcome horrific obstacles, the speaker is uniquely qualified to speak to the miraculous power of body, mind, spirit and the phenomenal potential every clinician has to make a positive impact.

Pharmacist Learning Objectives

Participants will recognize how they fit into the integral puzzle of patient care.
Participants will recognize the importance of working cohesively within the medical and social community to provide a wrap around.

Nurse Learning Objectives

Participants will recognize how they fit into the integral puzzle of patient care.
Participants will recognize the importance of working cohesively within the medical and social community to provide a wrap around.

Faculty

Colleen Alexander, Motivational Speaker, Athlete
Colleen Kelly Alexander

ACPE UAN

0798-0000-20-112-L04-P (Knowledge-Based)

0798-0000-20-112-L04-N (Knowledge-Based)

Credits
1

Handouts

20112L04_2pp.pdf

Supported By
PharmCon

Evaluating Oncology Biosimilars: Implementation Challenges and Opportunities

9:55 AM - 11:25 AM

It has been estimated that by 2026, biosimilars could lead to an estimated $50 billion reduction in direct spending on biologics in the U.S. Utilization of these agents, however, remains limited for a host of reasons. This session will review a multitude of challenges, including pending litigation and clinical/patient knowledge gaps, which have hindered implementation of biosimilars. Potential benefits of adopting oncology biosimilars will be addressed herein, including how to interpret FDA-required efficacy, safety, and immunogenicity studies. Finally, this session will review strategies for improved integration of biosimilars including considerations for formulary review and their incorporation into treatment pathways.

Pharmacist Learning Objectives

Define the challenges which have been encountered with the advent of oncology biosimilars in the U.S. market
Recognize the potential benefits of adopting supportive care and therapeutic oncology biosimilars
Identify appropriate strategies for optimal integration of oncology biosimilars into clinical practice

Nurse Learning Objectives

Define the challenges which have been encountered with the advent of oncology biosimilars in the U.S. market
Recognize the potential benefits of adopting supportive care and therapeutic oncology biosimilars
Identify appropriate strategies for optimal integration of oncology biosimilars into clinical practice

Faculty

Leigh Boehmer, Pharmd, BCOP
Medical Director, Association of Community Cancer Centers

ACPE UAN

0798-0000-20-113-L01-P (Application-Based)

0798-0000-20-113-L01-N (Application-Based)

Credits
1.5

Handouts

20113H01_2pp.pdf

Supported By
Novartis, Coherus

Development of Health-System Outpatient Specialty Pharmacy Programs: Trends, Benefits, and Challenges

12:35 PM - 1:35 PM

Specialty pharmaceuticals are a rapidly expanding market. A growing number of health-systems are leveraging their connection providers and this patient population to build their own specialty pharmacy delivery model. Stakeholders should be mindful of some of the current trends within the specialty pharmacy arena, and this presentation will highlight several of them. Additionally, pharmacists may want to know about some of the advantages that a specialty pharmacy offers with respect to patient care and the coordination of services. These will be reviewed along with some of the current challenges facing those within the specialty pharmacy space. Finally, the fundamental elements of a specialty pharmacy care model will be discussed for those pharmacists interested in understanding the process of implementing such a model within their own health-system.

Pharmacist Learning Objectives

Identify several current and important trends within specialty pharmacy
Describe some of the opportunities and advantages of an integrated health-system specialty pharmacy
Recognize key challenges that exist for the health-system specialty pharmacy business model
Identify some of the most significant considerations when deciding to build a health-system specialty pharmacy operation

Nurse Learning Objectives

Identify several current and important trends within specialty pharmacy
Describe some of the opportunities and advantages of an integrated health-system specialty pharmacy
Recognize key challenges that exist for the health-system specialty pharmacy business model
Identify some of the most significant considerations when deciding to build a health-system specialty pharmacy operation

Faculty

Jason Poquette, RPh, CSP
Director of Outpatient and Specialty Pharmacy, Dana-Farber Cancer Institute, Boston, MA

ACPE UAN

0798-0000-20-207-L04-P (Application-Based)

0798-0000-20-207-L04-N (Application-Based)

Credits
1

Handouts

20207H04_2pp.pdf

Supported By
Novartis

New CARs in Town

1:40 PM - 2:40 PM

This program will provide an overview of FDA approved chimeric antigen receptor T-cell therapies and their place in therapy. We will then discuss recent advances in cellular therapies, with updated information about novel targets and investigational products. Finally, we will discuss the toxicities commonly encountered in patients receiving CAR T-cell therapies and appropriate treatment strategies. Future directions will also be discussed.

Pharmacist Learning Objectives

Recognize currently approved CAR (Chimeric Antigen Receptor) T-cell therapies and their place in therapy
Identify novel CAR targets and treatments
Recognize relevant clinical trial data for CAR therapies in development
Recognize common toxicities associated with CAR T-cell therapies and identify appropriate management strategies

Nurse Learning Objectives

Recognize currently approved CAR (Chimeric Antigen Receptor) T-cell therapies and their place in therapy
Identify novel CAR targets and treatments
Recognize relevant clinical trial data for CAR therapies in development
Recognize common toxicities associated with CAR T-cell therapies and identify appropriate management strategies

Faculty

Larry Buie, PharmD, BCOP, FASHP
Clinical Pharmacy Manager, Lymphoma and BMT, Residency Program Director, PGY2 Oncology; Memorial Sloan Kettering Cancer Center

ACPE UAN

0798-0000-20-122-L01-P (Knowledge-Based)

0798-0000-20-122-L01-N (Knowledge-Based)

Credits
1

Handouts

20122H01_2pp.pdf

Supported By
Novartis

Safety Impacts and Considerations for Emerging Payor Coverage Policies

2:45 PM - 3:45 PM

Without a doubt, third party payor policies impact healthcare institutions and influence patient care regimens. This session seeks to explore and examine the potential safety impacts of emerging payor coverage policies by identifying site of care and preferred product guidelines. A focus is placed on medication safety and the pharmacist’s role in balancing safety with third party payor policies.

Pharmacist Learning Objectives

Identify site of care and preferred product guidelines
Recognize the impact of payor coverage policies on healthcare institutions and the medication use process
Identify the safety implications of payor policy changes on healthcare institutions and patient care

Nurse Learning Objectives

Identify site of care and preferred product guidelines
Recognize the impact of payor coverage policies on healthcare institutions and the medication use process
Identify the safety implications of payor policy changes on healthcare institutions and patient care

Faculty

Audrea Szabatura, PharmD, BCOP
Medication Safety Officer, Dana-Farber Cancer Institute

Aaron Poe, RHIA, CCS-P, CHC
Revenue Cycle Manager, Pharmacy and Clinical Support, Dana-Farber Cancer Institute

ACPE UAN

0798-0000-20-226-L05-P (Knowledge-Based)

0798-0000-20-226-L05-N (Knowledge-Based)

Credits
1

Handouts

20226L05_2pp.pdf

Supported By
Novartis

A Punch in the Gut: Updates in the Treatment of Advanced and Metastatic Gastrointestinal Cancers

4:15 PM - 5:15 PM

The landscapes of the treatment of advanced and metastatic upper and lower gastrointestinal cancers and hepatobiliary cancers are ever changing. Traditional agents have garnered expanded indications and the ability to identify biomarkers that drive the development of GI cancers has added numerous tools to our treatment armamentarium. This presentation will cover recent updates to literature and evidence-based practice in the management of GI cancer patients. Changes to therapy for advanced or metastatic gastric cancer, colorectal cancer, hepatocellular carcinoma, and intrahepatic cholangiocarcinoma will be reviewed.

Pharmacist Learning Objectives

Identify new treatment modalities used in the setting of advanced or metastatic upper and lower gastrointestinal cancers.
Identify new treatment modalities used in the setting of advanced or metastatic hepatobiliary cancers.
Compare the efficacy data and toxicity profiles of novel medication regimens for the treatment of various gastrointestinal cancers.

Nurse Learning Objectives

Identify new treatment modalities used in the setting of advanced or metastatic upper and lower gastrointestinal cancers.
Identify new treatment modalities used in the setting of advanced or metastatic hepatobiliary cancers.
Compare the efficacy data and toxicity profiles of novel medication regimens for the treatment of various gastrointestinal cancers.

Faculty

Jesse Mack, PharmD, BCPS, BCOP
Clinical Pharmacist Hematology/Oncology, Cone Health Cancer Center

ACPE UAN

0798-0000-20-116-L01-P (Knowledge-Based)

0798-0000-20-116-L01-N (Knowledge-Based)

Credits
1

Handouts

20116L01_2pp.pdf

Supported By
Merck & Co., Inc, Taiho, Novartis

Scheduled CE Activities Friday, October 9, 2020

NEHOPS Day 2 - Opening Remarks

7:45 AM - 8:00 AM

Join Pharmacist Kevin Hope for an introduction and welcome to the second day of NEHOPS.

Faculty

Kevin Hope, RPh
Clinical Education Specialist and Continuing Education Administrator, PharmCon, Inc.; Advisory Board Member, Paradigm Education Solutions; Nuclear Pharmacist, Triad Isotopes

ACPE UAN

Credits
0

Handouts

Supported By
PharmCon

COVID-19 Experience & Impact on Oncology Pharmacy Practice

8:00 AM - 9:00 PM

This presentation will focus on the changes that occurred in the various areas of oncology pharmacy practice as a result of the COVID-19 pandemic. The practice changes that will be discussed include the following: pharmacist remote order verification, telehealth consults for medication assessment and education, advance medication preparation, route of drug administration changes, expanded use of drug administration in the home, the alteration of specific chemotherapy dosing and regimens, and management of patients on a clinical trial. The COVID-19 pandemic forced these major changes to oncology pharmacy practice in a few short weeks. However, these changes will have a lasting impact on the future care of oncology patients.

Pharmacist Learning Objectives

Outline the areas of pharmacy practice that were affected by the COVID-19 pandemic
Identify specific operational and clinical practice changes that were implemented during the COVID-19 pandemic
Discuss how these practice changes will shape the future of oncology pharmacy

Nurse Learning Objectives

Outline the areas of pharmacy practice that were affected by the COVID-19 pandemic
Identify specific operational and clinical practice changes that were implemented during the COVID-19 pandemic
Discuss how these practice changes will shape the future of oncology pharmacy

Faculty

Sylvia Bartel, MPH
Director of Pharmacy and Clinical Support Services, Dana Farber Cancer Institute

ACPE UAN

0798-0000-20-227-L01-P (Knowledge-Based)

0798-0000-20-227-L01-N (Knowledge-Based)

Credits
1

Handouts

20227L01_2pp.pdf

Supported By
Novartis

Cancer Patient Access to Unapproved New Drugs: From Laetrile to Project Facilitate

9:05 AM - 10:05 AM

This program will focus on the United States Supreme Court case of Rutherford v. United States, in which the court determined that cancer patients could not legally use the unapproved drug laetrile. Legal principles from the federal Food, Drug & Cosmetic Act will be explained, within the context of this case. The Abigail Alliance case will also be discussed as context for state and federal “right to try” legislation. FDA’s expanded access programs will be described, including the recently adopted “Project Facilitate” that has been implemented to broaden eligibility of cancer patients and reduce the workload in qualifying cancer patients for the use of unapproved cancer therapies.

Pharmacist Learning Objectives

Evaluate legal arguments from the case of Rutherford v. United States, related to the use of unapproved laetrile products by cancer patients.
Identify the legal principles applicable to new drug approval and the availability of unapproved new drugs.
Compare the "Right to Try" law with the FDA's "Project Facilitate."

Nurse Learning Objectives

Evaluate legal arguments from the case of Rutherford v. United States, related to the use of unapproved laetrile products by cancer patients.
Identify the legal principles applicable to new drug approval and the availability of unapproved new drugs.
Compare the "Right to Try" law with the FDA's "Project Facilitate."

Faculty

David Brushwood, JD, RPh
Senior Lecturer, University of Wyoming School of Pharmacy

ACPE UAN

0798-0000-20-119-L03-P (Knowledge-Based)

0798-0000-20-119-L03-N (Knowledge-Based)

Credits
1

Handouts

20119L03_2pp.pdf

Supported By
Novartis

Advances in Front-Line Treatment of CLL: Is Chemoimmunotherapy Obsolete?

10:10 AM - 11:10 AM

The presentation will cover the landmark chemoimmunotherapy trials including FCR (CLL8) and BR (Eichorst, et al. Lancet. 2016). In addition, the landmark studies for the novel front-line agents will be reviewed for ibrutinib (RESONATE-2, ALLIANCE, iLLUMINATE, E1912), acalabrutinib (ELEVATE-TN), and venetoclax (CLL14). After the clinical trials are summarized, toxicity and administration of these front-line treatments will be reviewed to fulfil the second objective. Before transitioning into upcoming clinical data, a patient case(s) will be used to assess the audiences understanding of picking a front-line agent based on specific patient factors. Lastly, CLL remains a rapidly evolving field with many upcoming trials that have the potential to significantly impact front-line treatment of CLL. This will be highlighted in the CAPTIVATE study (ibrutinib + venetoclax), AVO regimen (acalabrutinib + venetolcax + obinutuzumab), LOXO-305, zanubrutinib, and ublituximab/umbralisib. Less time will be spent on the specifics of these clinical trials since only preliminary data is available from ASH. The third objective goal is to highlight the evolving treatment schema that involves novel treatment only, utilizes a time-definitive treatment approach, and targets early MRD negativity.

Pharmacist Learning Objectives

Compare and contrast the recommended front-line regimens for the treatment of chronic lymphocytic leukemia (CLL)
Recognize patient-specific characteristics in the selection of an appropriate front-line treatment regimen for CLL
Identify upcoming clinical trials and the potential impact on selection of front-line treatment

Nurse Learning Objectives

Compare and contrast the recommended front-line regimens for the treatment of chronic lymphocytic leukemia (CLL)
Recognize patient-specific characteristics in the selection of an appropriate front-line treatment regimen for CLL
Identify upcoming clinical trials and the potential impact on selection of front-line treatment

Faculty

Charlene Kabel, PharmD, BCOP
Clinical Pharmacy Specialist - Leukemia, Memorial Sloan Kettering Cancer Center, New York, NY

ACPE UAN

0798-0000-20-114-L01-P (Application-Based)

0798-0000-20-114-L01-N (Application-Based)

Credits
1

Handouts

20114L04_2pp.pdf

Supported By
Novartis, Pharmacyclics and Janssen

Cancer Immunotherapy - Where We Are and Where We’re Heading

12:50 PM - 1:50 PM

This talk will highlight the current landscape of ICIs, their expanded indications to many malignancies, and the current limitations of these drugs due to both primary and secondary resistance. We will also discuss the future of immune checkpoint inhibitors and explore the current development of bi-specific antibodies and adaptive T-cell therapy in solid tumors. This new wave of immunotherapeutics is a promising targeted approach that may overcome tumor resistance to immune checkpoint inhibitors by directing the immune cells to their targets on tumor cells. However, this novel approach comes with the cost of severe toxicities including cytokine release syndrome.

Pharmacist Learning Objectives

Recognize the current status of immune checkpoint inhibitor (ICI) indications
Identify trends for the next wave of ICIs including bi-specific antibodies and adaptive T-cell therapy in solid tumors
Recognize the toxicities of these novel immunotherapy approaches

Nurse Learning Objectives

Recognize the current status of immune checkpoint inhibitor (ICI) indications
Identify trends for the next wave of ICIs including bi-specific antibodies and adaptive T-cell therapy in solid tumors
Recognize the toxicities of these novel immunotherapy approaches

Faculty

Osama Rahma, MD
Assistant Professor of Medicine Department of Medicine; Harvard Medical School

ACPE UAN

0798-0000-20-209-L01-P (Knowledge-Based)

0798-0000-20-209-L01-N (Knowledge-Based)

Credits
1

Handouts

20209H01_2pp.pdf

Supported By
Merck & Co., Inc, Novartis

The Next Steps in Multiple Myeloma: A review of New and Emerging Treatment Options

1:55 PM - 2:55 PM

The majority of patients with multiple myeloma (MM) will have a response to current treatments, either with conventional chemotherapy agents, transplant or the combination. However, conventional therapies are not curative and most of these patients will ultimately progress. The are a number of new therapies which have recently been approved in the treatment of R/R MM including a selective inhibitor of nuclear export compound, and a Bcl-2 inhibitor. Newer therapies and first in class treatment are expected to be approved shortly including chimeric antigen receptor T-cell therapy and bispecific T-cell engager antibody. These novel agents require careful management of patients as well as precise monitoring for side effects. The goal of this presentation will be to improve the awareness of new regimens for R/R MM and provide models of care for the management of these therapies side effects.

Pharmacist Learning Objectives

Recognize the clinical significance of new approvals for the treatment of relapsed/refractory(R/R) Multiple Myeloma
Summarize new treatment therapies for Multiple myeloma including chimeric antigen receptor T-cell therapy and bispecific T-cell engager antibody therapy
Identify practice-changing data with side effect management that may be effectively employed to manage patients with R/R MM

Nurse Learning Objectives

Recognize the clinical significance of new approvals for the treatment of relapsed/refractory(R/R) Multiple Myeloma
Summarize new treatment therapies for Multiple myeloma including chimeric antigen receptor T-cell therapy and bispecific T-cell engager antibody therapy
Identify practice-changing data with side effect management that may be effectively employed to manage patients with R/R MM

Faculty

Ali McBride, PharmD, MS, BCOP, FAzPA, FASHP
UACC

ACPE UAN

0798-0000-20-123-L01-P (Knowledge-Based)

0798-0000-20-123-L01-N (Knowledge-Based)

Credits
1

Handouts

20123L01_2pp.pdf

Supported By
Sanofi Genzyme, Novartis

Updates in GU Malignancies: Navigating the Changing Landscape of Treatment

3:25 PM - 4:25 PM

This session will review recently approved treatments or those recently incorporated into evidence-based guidelines for the treatment of urothelial, kidney, and prostate cancers to provide. Important pharmacologic information will be provided, such as an overview of pharmacology, pharmacokinetics, common adverse events, contraindications, and appropriate monitoring. Key clinical trial information will be discussed and analyzed such that the pharmacist will be able to understand which patients may most benefit from one of these new treatments. Finally, recommendations for managing adverse effects will be provided.

Pharmacist Learning Objectives

Identify recently approved or emerging treatments options for urothelial, kidney, and prostate cancers and how they differ from those currently used
Recognize the importance of integrating new and/or emerging therapies for treatment of urothelial, kidney, and prostate cancers into the current treatment paradigm
Recognize appropriate interventions to prevent and manage adverse effects of these newly approved treatments urothelial, kidney, and prostate cancers

Nurse Learning Objectives

Identify recently approved or emerging treatments options for urothelial, kidney, and prostate cancers and how they differ from those currently used
Recognize the importance of integrating new and/or emerging therapies for treatment of urothelial, kidney, and prostate cancers into the current treatment paradigm
Recognize appropriate interventions to prevent and manage adverse effects of these newly approved treatments urothelial, kidney, and prostate cancers

Faculty

Lisa Holle, PharmD, BCOP, FHOPA, ISOPP
Associate Clinical Professor, UConn School of Pharmacy, Storrs, CT

ACPE UAN

0798-0000-20-115-L01-P (Knowledge-Based)

0798-0000-20-115-L01-N (Knowledge-Based)

Credits
1

Handouts

20115L01_2pp.pdf

Supported By
Merck & Co., Inc, Novartis, Astellas, and Pfizer, Inc.

Scheduled CE Activities Saturday, October 10, 2020

NEHOPS Day 3 - Opening Remarks

7:45 AM - 8:00 AM

Join Pharmacist Kevin Hope for an introduction and welcome to the final day of NEHOPS.

Faculty

Kevin Hope, RPh
Clinical Education Specialist and Continuing Education Administrator, PharmCon, Inc.; Advisory Board Member, Paradigm Education Solutions; Nuclear Pharmacist, Triad Isotopes

ACPE UAN

Credits
0

Handouts

Supported By
PharmCon

Herbal Supplements, Patient Safety and Drug Interactions - Oh My!

8:35 AM - 9:35 AM

This session will describe the current landscape of herbal supplement use in oncology. Examples of more commonly used herbals will be discussed in detail. Resources available to providers and patients will be reviewed and applied to describe how to evaluate products for patient safety, potential efficacy and presence of drug-drug and drug-disease state interactions. The session will conclude with clinical pearls for discussing herbal use with a patient.

Pharmacist Learning Objectives

Recognize the epidemiology of herbal supplements in oncology
Identify the pros and cons of more commonly used herbal supplements
Recognize resources available for product evaluation with a focus on safety, efficacy, and potential interactions
Identify clinical pearls for discussing herbal supplement use with a patient

Nurse Learning Objectives

Recognize the epidemiology of herbal supplements in oncology
Identify the pros and cons of more commonly used herbal supplements
Recognize resources available for product evaluation with a focus on safety, efficacy, and potential interactions
Identify clinical pearls for discussing herbal supplement use with a patient

Faculty

Ashley Glode, PharmD, BCOP
Assistant Professor, University of Colorado Skaggs School of Pharmacy and Pharmaceutical Sciences

ACPE UAN

0798-0000-20-125-L01-P (Application-Based)

0798-0000-20-125-L01-N (Application-Based)

Credits
1

Handouts

20125L04_2pp.pdf

Supported By
Novartis

A Pathway-Based Approach to Targeted Therapy in Cancer: Rationalizing Outcomes with Molecular Pharmacology

9:40 AM - 10:40 AM

The integration of targeted therapeutics into cancer care has transformed the field and provided patients with better outcomes. This logarithmic growth in the number of unique mechanisms of action of anti-tumor agents has led to an increased need for pathway competence as a clinical pharmacist to help to optimize therapy. A better understanding of upstream and downstream regulators of drug targets help to inform rational adverse effect profiles, mechanisms of drug resistance, as well as potential sensitivity for off-label drug use. In this session, we will discuss some of the most commonly targeted pathways in cancer care and how to utilize this knowledge to provide the highest level of patient care possible.

Pharmacist Learning Objectives

Define the action of molecular pathways in oncology
Recognize common oncogenic pathways and their regulatory consequences
Connect common therapeutic targets with upstream and downstream regulators
Integrate molecular system connections with rational clinical outcomes

Nurse Learning Objectives

Define the action of molecular pathways in oncology
Recognize common oncogenic pathways and their regulatory consequences
Connect common therapeutic targets with upstream and downstream regulators
Integrate molecular system connections with rational clinical outcomes

Faculty

Nathan Seligson, BS, PharmD
Clinical Assistant Professor, Department of Pharmacotherapy and Translational Research, Diversion of Translational Research, The University of Florida, Jacksonville, FL

ACPE UAN

0798-0000-20-124-L01-P (Knowledge-Based)

0798-0000-20-124-L01-N (Knowledge-Based)

Credits
1

Handouts

20124L01_2pp.pdf

Supported By
Merck & Co., Inc, Novartis

USP <800> Keeping Patients and Practitioners Safe

10:45 AM - 12:15 PM

USP <800> was published in 2016 and became official in 2019. It is designed to protect patients, personnel, and the environment. Required elements include facility issues, personnel training, use of closed system drug-transfer devices, and work practices that support containment and elimination of hazards. This session will review strategies to improve compliance of the essential protective components.

Pharmacist Learning Objectives

Recognize how the NIOSH Hierarchy of Risk applies to <800>
Identify the key facility components required by <800>
Cite resources to assess closed system drug-transfer devices
State three work practices that support containment of hazardous drugs

Nurse Learning Objectives

Recognize how the NIOSH Hierarchy of Risk applies to <800>
Identify the key facility components required by <800>
Cite resources to assess closed system drug-transfer devices
State three work practices that support containment of hazardous drugs

Faculty

Patricia Kienle, RPh, MPA, FASHP
Director of Accreditation and Medication Safety, Cardinal Health Innovative Delivery Solutions

ACPE UAN

0798-0000-20-121-L07-P (Knowledge-Based)

0798-0000-20-121-L07-N (Knowledge-Based)

Credits
1.5

Handouts

20121H07_2pp.pdf

Supported By
Novartis

Updates in the Treatment of Breast Cancer- A Focus on Trends in Metastatic Triple Negative and HER2+ Disease

1:25 PM - 2:25 PM

The treatment of early stage and metastatic breast cancer is constantly evolving. This session will explore the data behind various recent FDA drug approvals for breast cancer and how these approvals change treatment guidelines. In HER2-positive breast cancer, the approval of tucatinib and fam-trastuzumab deruxtecan in the metastatic setting have changed the treatment landscape. Immunotherapy gained approval for metastatic triple negative breast cancer, but only displayed clinical benefit in a subset of patients. Sacituzumab govitecan became the first FDA approved medication specifically for triple negative breast cancer and provides a late stage treatment option for these patients. The session will also discuss other recent FDA approvals in breast cancer and changes to treatment guidelines.

Pharmacist Learning Objectives

Recognize the changing landscape in the treatment of metastatic HER-2 positive breast cancer
Determine the role of immunotherapy in the treatment of breast cancer
Indicate the setting and use of recently approved agents for metastatic triple negative and HER2+ breast cancer

Nurse Learning Objectives

Recognize the changing landscape in the treatment of metastatic HER-2 positive breast cancer
Determine the role of immunotherapy in the treatment of breast cancer
Indicate the setting and use of recently approved agents for metastatic triple negative and HER2+ breast cancer

Faculty

Craig Vargo, PharmD, BCOP
Specialty Practice Pharmacist - Breast Oncology, The Ohio State University Wexner Medical Center - The James Cancer Hospital, Columbus, OH

ACPE UAN

0798-0000-20-126-L01-P (Knowledge-Based)

0798-0000-20-126-L01-N (Knowledge-Based)

Credits
1

Handouts

20126L01_2pp

Supported By
Seattle Genetics, Novartis, Immunomedics, Inc.

How Did We Get Here? Pharmacy Burnout, Etiology, Consequences, and Solutions

2:55 PM - 3:55 PM

Everyone talks about it, but little seems to be accomplished. Burnout appears rampant in all areas of healthcare, but particularly pharmacy regardless of setting.

What are the unique causes of burnout in pharmacists? What trends are we observing in the literature? Is there hope for pharmacy to become unburned? In this presentation, you will learn the answers to these questions. By the end, you'll have a better understanding of how your institution influences your job satisfaction and ideas on how your work environment could improve.

Pharmacist Learning Objectives

Recognize job-related stress, burnout, and other psychological issues and trends in pharmacy
Identify burnout symptoms, consequences, and causes
Determine personal and organizational factors that lead to burnout
Specify personal and organizational burnout interventions

Nurse Learning Objectives

Recognize job-related stress, burnout, and other psychological issues and trends in pharmacy
Identify burnout symptoms, consequences, and causes
Determine personal and organizational factors that lead to burnout
Specify personal and organizational burnout interventions

Faculty

Alex Barker, PharmD
Founder, The Happy PharmD

ACPE UAN

0798-0000-20-120-L04-P (Knowledge-Based)

0798-0000-20-120-L04-N (Knowledge-Based)

Credits
1

Handouts

20120H04_2pp.pdf

Supported By
PharmCon

PharmCon is accredited by the Accreditation Council for Pharmacy Education as a provider of continuing pharmacy education

Requirements for CE Credit

Participant Requirement and Statement of Credit: To receive credit, participants must fully attend each session and complete the pre and post evaluations (no partial credit will be awarded). Attendance will be verified, and CE credit will be issued through our webinar platform . All participants will have the opportunity to evaluate the educational sessions and presenters as well as the ability to identify their future educational needs.
Pharmacists and Pharmacy Technicians: CE credit will be automatically uploaded to CPE Monitor upon completion of the evaluation and posted to the participant’s NABP account within 72 hours where an official certificate of credit can be printed. Evaluations must be completed within 60 days of program date to receive credit.
Statement of Disclosure: Disclosure will be made on the day of the program regarding any interest or affiliation a speaker may have with a supporting organization.
Refund Policy: A full refund will be provided only if a written request is received by American Health Resources, LLC at least 48 hours prior to the program or if the program is cancelled. American Health Resources, LLC reserves the right to change the presenters, topics or seminar schedules.

Only Certificates of Credit issued from CPE Monitor are valid in the US.
CPE Monitor will not accept credits after 60 days from the session date.

Supported By:
PharmCon, Immunomedics, Inc., Coherus, Novartis, Sanofi Genzyme, Merck & Co., Inc, Seattle Genetics, Astellas, Pfizer, Inc., Taiho, Pharmacyclics and Janssen

Registration closes on 10/10/2020 at 5:30 PM